Thus, we could speculate that the higher expression of plasma HSP90α, the more lung cancer tissues with HIF-1α positivity, which may affect the expression of PD-L1, affecting the efficacy of immunotherapy. The gene discussed is HSP90AA1; the disease is lung carcinoma.